Global Viral Vector Manufacturing Research Report 2018

DUBLIN, Oct. 22, 2018 /PRNewswire/ --

The "Global Viral Vector Manufacturing Markets and Technologies Through 2022" report has been added to's offering.

The report provides an analysis based on each market segment, which includes by type, disease and application. The global viral vector vaccine manufacturing market by type is further segmented on the basis of adenoviral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, cytomegalovirus, pox virus and other viral vectors.

Rising prevalence of human chronic diseases and veterinary diseases across the globe is propelling the adoption of viral vector vaccines because vaccines are recognized to be the most cost-effective and efficient medium. According to World Health Organization (WHO), the number of patients suffering from chronic diseases such as cancer, chronic respiratory diseases, cardiovascular diseases and others was noted at about 130 million people in 2005 and is expected to reach around 173 million by 2030.

Moreover, according to the WHO World Health Statistics report, cardiovascular disease, cancer and chronic respiratory disease caused around 17.9 million, 9 million and 3.8 million, respectively, which in total accounts for 75% of noncommunicable disease deaths across the globe. In addition, according to Avert Organization (U.K.), in 2016, approximately 36.7 million people were found to be suffering from human immunodeficiency virus (HIV), and 1 million people died due to HIV-related diseases in 2016.

Furthermore, according to the report, in 2016, 5.1 million new cases of acquired immune deficiency syndrome (AIDS) were registered in Asia-Pacific, compared with 0.23 million in North Africa and the Middle East. Moreover, Sub-Saharan Africa registered the highest prevalence of AIDS, with more than 19 million infected by HIV in 2016.

Moreover, increasing veterinary diseases such as avian influenza, Marek's disease, infectious bronchitis Peste des Petits Ruminants (PPR) disease and others are also becoming a global concern. According to the U.S. Department of Health and Human Services, the number of rabid dogs increased from 59 in 2014 to 67 in 2015. Moreover, according to the report, 92.4% of rabies cases were found in wild animals. In 2015, according to the American Veterinary Medical Association, 5,508 cases of rabies have been reported in U.S., including 5,088 wildlife cases. Therefore, rising cases of veterinary and human chronic diseases is propelling the viral vector vaccine manufacturing market. Companies and government institutes are performing continuous research activities to develop viral-vector-based vaccines. Viral vector vaccines are more cost-effective and efficient than conventional vaccines.

Viral-vector-based vaccines have the ability to enrich immunogenicity without an adjuvant and induce a vigorous cytotoxic T lymphocyte (CTL) response to abolish virus-infected cells. For instance, Royal Free Hospital (U.K.) and Oxford University Hospital (U.K.), in 2017, were involved in Phase I clinical trial of the adeno-associated viral vector (FLT180a) in patients with hemophilia B. Moreover, in 2017, the Orthopaedic Hemophilia Treatment Center (California), Medical University of South Carolina (MUSC), (South Carolina), Gulf States Hemophilia and Thrombophilia Center (Texas) were involved in a Phase II trial of BAX 888 drug, an adeno-associated virus serotype 8 (AAV8) vector expressing B-domain-deleted factor VIII (BDD-FVIII) in severe hemophilia A subjects administered a single intravenous infusion.

Key Topics Covered:

Chapter 1 Introduction

    --  Study Goals and Objectives
    --  Reasons for Doing This Study
    --  Scope of Report
    --  Methodology
    --  Geographic Breakdown
    --  Analyst's Credentials
    --  Custom Research
    --  Related Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

    --  Evolution and Transition
    --  Market Potential
    --  WHO
    --  U.S.
    --  European Union
    --  Australia
    --  Japan
    --  India
    --  China
    --  Market Segmentation
    --  Segmentation by Type
    --  Segmentation by Application
    --  Segmentation by Disease
    --  Regional Analysis
    --  North America
    --  Europe
    --  Asia-Pacific
    --  ROW

Chapter 4 Market Drivers

    --  Rising Number of Clinical Trials in Viral Vectors
    --  Growing Number of Gene Therapy Candidates
    --  Surging Investment in Gene-Therapy-Based R&D Activities
    --  Increasing Prevalence of Genetic Disorders and Chronic Diseases

Chapter 5 Market Breakdown by Type

    --  Overview
    --  Adenoviral Vectors
    --  Retroviral Vectors
    --  Lentiviral Vectors
    --  Adeno-associated Viral Vectors
    --  Cytomegalovirus
    --  Pox Virus
    --  Other Viral Vectors

Chapter 6 Market Breakdown by Disease Application

    --  Overview
    --  Human Disease Applications
    --  Overview
    --  Hepatitis
    --  Cancer
    --  Influenza
    --  HIV
    --  Tuberculosis
    --  Malaria
    --  Others
    --  Veterinary Disease Applications
    --  Avian Influenza
    --  Marek's Disease
    --  Infectious Bronchitis
    --  PPR Disease
    --  Others (Rabies, FMD, Swine Influenza, Equine Influenza, Newcastle
        Disease, etc.)

Chapter 7 Market Breakdown by Application Type

    --  Overview
    --  Multivalent Viral Vector Vaccines
    --  Multipathogen Viral Vector Vaccines

Chapter 8 Market Breakdown by Region

    --  North America
    --  U.S.
    --  Canada
    --  Mexico
    --  Europe
    --  Germany
    --  U.K.
    --  France
    --  Spain
    --  Italy
    --  Rest of Europe
    --  Asia-Pacific
    --  China
    --  India
    --  Japan
    --  Australia
    --  South Korea
    --  Rest of Asia-Pacific
    --  Rest of the World (ROW)
    --  Latin America
    --  Middle East and Africa

Chapter 9 Viral Vector Manufacturing Industry Structure

    --  Viral Vector Manufacturing Supply Chain
    --  Common Steps Followed in Small-Scale Manufacturing of Adenovirus
    --  Step 1: Cell Lysis and Genomic DNA Breakdown
    --  Step 2: Clarification
    --  Step 3: Concentration
    --  Steps 4 and 5: Anion Exchange and Gel Filtration
    --  Step 6: Membrane Filtration
    --  Companies Involved in Developing Lentiviral Vector Candidates
    --  Companies Involved in Developing Adeno-associated Vector (AAV)
    --  Manufacturer Purchasing Criteria
    --  Innovation within the Viral Vector Vaccine Manufacturing Industry
    --  Competitive Landscape
    --  Expansions
    --  Collaborations
    --  Investments
    --  Acquisitions

Chapter 10 Patent Analysis

    --  U.S. Patent Analysis
    --  European Patent Analysis
    --  Japanese Patent Analysis

Chapter 11 Company Profiles

    --  Advanced Bioscience Laboratories, Inc.
    --  Advanced Biotherapeutics Consulting
    --  Applied Viromics
    --  Batavia Biosciences
    --  Benitec Biopharma
    --  Biogen Idec (Now Biogen, Inc.)
    --  Biovian
    --  Boehringer Ingelheim Gmbh
    --  Brammer Bio
    --  Cell And Gene Therapy Catapult
    --  Ceva Corporate
    --  Cobra Biologics (Subsidiary Of Recip Ab)
    --  Creative Biogene
    --  GE Healthcare
    --  Genedetect
    --  Genvec Inc. (Subsidiary Of Intrexon Corp.)
    --  ID Pharma Co. Ltd.
    --  Janssen Pharmaceutical Companies Of Johnson & Johnson
    --  Lonza
    --  Merck Millipore
    --  Miltenyi Biotec
    --  Molmed Spa
    --  Paragon Bioservices Inc.
    --  Pfizer Inc.
    --  Sanofi
    --  Sementis
    --  Spark Therapeutics Inc.
    --  Synpromics
    --  Valneva
    --  Vector Biolabs
    --  Vigene Biosciences Inc.

    --  Virovek

For more information about this report visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets